ethyl 2,5-dimethyl-1-phenyl-1H-imidazole-4-carboxylate | 1261181-07-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl 2,5-dimethyl-1-phenyl-1H-imidazole-4-carboxylate
• 英文别名: ethyl 2,5-dimethyl-1-phenylimidazole-4-carboxylate
• CAS: 1261181-07-0
• 化学式: C₁₄H₁₆N₂O₂
• 分子量: 244.293
• InChiKey: ZWNLWHGHXDQHDE-UHFFFAOYSA-N

物化性质

• 沸点：
  394.6±34.0 °C(Predicted)
• 密度：
  1.12±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 2,5-dimethyl-1-phenyl-1H-imidazole-4-carboxylate 在 N-甲基吗啉 、 lithium hydroxide monohydrate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 27.0h， 生成 N-(3-(4-(2,3-dichlorophenyl)piperazin-1-yl)propyl)-2,5-dimethyl-1-phenyl-1H-imidazole-4-carboxamide dihydrochloride
  参考文献：
  名称：

  Design and Synthesis of Novel Arylpiperazine Derivatives Containing the Imidazole Core Targeting 5-HT_2A Receptor and 5-HT Transporter

  摘要：

  Serotonin antagonist reuptake inhibitor (SARI) drugs that block both 5-HT2 receptors and the serotonin transporters have been developed. The human 5-HT2A/2C receptor has been implicated in several neurological conditions, and potent selective 5-HT2A/2C ligands may have therapeutic potential for treatment of CNS diseases such as depression. An imidazole moiety usually provides good pharmacokinetic properties as a drug substance, and thus considerable efforts have been devoted to develop imidazole derivatives into drug candidates. The imidazole series of compounds was evaluated against 5-HT2A/2C and serotonin reuptake inhibition. A few of the compounds in the series showed promising IC50 values and antidepressant-like effect in in vivo forced swimming test (FST). On the basis of these results, further lead optimization studies resulted in identifying promising compounds potentially for therapeutic use.

  DOI：

  10.1021/jm200682b
• 作为产物：
  描述：

  乙酰乙酸乙酯 在 palladium 10% on activated carbon 氢气 、 溶剂黄146 、 三氟乙酸 、 sodium nitrite 作用下， 以 丁腈 、 乙醇 、 水 为溶剂， 反应 19.67h， 生成 ethyl 2,5-dimethyl-1-phenyl-1H-imidazole-4-carboxylate
  参考文献：
  名称：

  [EN] NOVEL ARYLPIPERAZINE-CONTAINING IMIDAZOLE 4-CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
  [FR] NOUVEAUX DÉRIVÉS IMIDAZOLE-4-CARBOXAMIDE CONTENANT DE L'ARYLPIPÉRAZINE ET COMPOSITION PHARMACEUTIQUE CONTENANT CES DÉRIVÉS

  摘要：

  公开号：

  WO2011005052A8

文献信息

• [EN] AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS<br/>[FR] DÉRIVÉS AZASPIRO EN TANT QU'ANTAGONISTES DE TRPM8
  申请人：RAQUALIA PHARMA INC

  公开号：WO2015136947A1

  公开（公告）日：2015-09-17

  The present invention relates to azaspiro derivatives of the formula (I) or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the TRPM8 receptor.

  本发明涉及式(I)的氮杂环螺环衍生物或其药用可接受盐或前药，其制备方法，含有它们的药物组合物以及它们在治疗通过TRPM8受体介导的各种疾病中的应用。
• 1H-imidazole derivatives as cannabinoid CB2 receptor modulators
  申请人：Lange H.M. Josephus

  公开号：US20060194779A1

  公开（公告）日：2006-08-31

  The invention relates to a group of 1H-imidazole derivatives which are modulators of cannabinoid CB 2 receptors, to methods for the preparation of these compounds, to novel intermediates useful for the synthesis of said imidazole derivatives, to methods for the preparation of these intermediates, to pharmaceutical compositions containing one or more of these 1H-imidazole derivatives as active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which cannabinoid CB 2 receptors are involved. The compounds have the general formula (I) wherein R 1 -R 4 have the meanings given in the specification.

  该发明涉及一组1H-咪唑衍生物，它们是大麻素CB2受体调节剂，涉及制备这些化合物的方法，有用于合成该咪唑衍生物的新型中间体，制备这些中间体的方法，含有一种或多种这些1H-咪唑衍生物作为活性成分的药物组合物，以及将这些药物组合物用于治疗涉及大麻素CB2受体的疾病。这些化合物具有通式（I），其中R1-R4具有规范中给出的含义。
• BICYCLIC HETEROCYCLIC COMPOUND
  申请人：Astellas Pharma Inc.

  公开号：US20140249151A1

  公开（公告）日：2014-09-04

  [Problem] To provide a compound useful as an active ingredient of a pharmaceutical composition for treating 11β-hydroxysteroid dehydrogenase type 1-related diseases such as dementia, schizophrenia, depression, pain (particularly, neuropathic pain or fibromyalgia), diabetes (particularly, type II diabetes mellitus), insulin resistance and the like. [Means for Solution] A bicyclic heterocyclic compound (the bicyclic heterocycle is formed when a cyclohexane ring is fused with a 5- to 6-membered monocyclic heterocycle that has only a nitrogen atom as a hetero atom) substituted with an acylamino group such as a (hetero)aroylamino group or the like or a pharmaceutically acceptable salt thereof was found to have an excellent selective inhibitory action against 11β-HSD1. Accordingly, the bicyclic heterocyclic compound of the present invention can be used for treating dementia, schizophrenia, depression, pain (particularly, neuropathic pain or fibromyalgia), diabetes (particularly, type II diabetes mellitus), insulin resistance, and the like.

  提供一种化合物，作为药物组合物的有效成分，用于治疗与11β-羟基类固醇脱氢酶1相关的疾病，如痴呆症、精神分裂症、抑郁症、疼痛（尤其是神经病性疼痛或纤维肌痛）、糖尿病（尤其是2型糖尿病）、胰岛素抵抗等。解决方法是发现一种带有酰胺基（如（杂）芳酰胺基等）或其药用可接受盐的取代的双环杂环化合物（当环己烷环与仅有氮原子作为杂原子的5-至6-成员单环杂环融合时形成双环杂环化合物），发现其对11β-HSD1具有出色的选择性抑制作用。因此，本发明的双环杂环化合物可用于治疗痴呆症、精神分裂症、抑郁症、疼痛（尤其是神经病性疼痛或纤维肌痛）、糖尿病（尤其是2型糖尿病）、胰岛素抵抗等。
• NOVEL ARYLPIPERAZINE-CONTAINING IMIDAZOLE 4-CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
  申请人：Lee Jinhwa

  公开号：US20120115881A1

  公开（公告）日：2012-05-10

  A novel arylpiperazine-containing imidazole 4-carboxamide derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating a depressive disorder are provided.

  本发明提供了一种新的含有芳基哌嗪基的咪唑-4-羧酰胺衍生物或其药学上可接受的盐，并且提供了一种以其为活性成分的制药组合物，用于预防或治疗抑郁症。
• Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same
  申请人：Lee Jinhwa

  公开号：US08835436B2

  公开（公告）日：2014-09-16

  A novel arylpiperazine-containing imidazole 4-carboxamide derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating a depressive disorder are provided.

  本发明提供了一种新的含有芳基哌嗪基和咪唑-4-羧酰胺衍生物或其药学上可接受的盐，以及一种包含该衍生物作为活性成分的药物组合物，用于预防或治疗抑郁症。